PMID- 15577155
OWN - NLM
STAT- MEDLINE
DCOM- 20050317
LR  - 20061115
IS  - 0917-5857 (Print)
IS  - 0917-5857 (Linking)
VI  - 14
IP  - 11
DP  - 2004 Nov
TI  - [Cost-effectiveness of osteoporosis treatment].
PG  - 39-45
AB  - With Japan's rapidly aging population, a remarkable increase in fragility 
      fractures due to osteoporosis and exhaustion of medical care resources is 
      anticipated. Therefore, the cost-effectiveness of osteoporosis treatment will be 
      more important than ever before. Because the outcome is estimated in terms of 
      gain of life time and improvement in quality of living, a treatment is judged to 
      be cost-effective when its cost per quality adjusted life year (QYALY) gained is 
      below an acceptable threshold. According to studies in Western countries, 
      medicines in use today including alendronate, risedronate, calcium plus vitamin 
      D, calcitonin and raloxifene are cost-effective. However, studies on the 
      cost-effectiveness of osteoporosis treatment based on Japanese data are thought 
      to be needed for Japanese patients.
FAU - Harada, Atsushi
AU  - Harada A
AD  - National Center for Geriatrics and Geroritology, Dept of Functional Restoration.
FAU - Ohta, Toshiki
AU  - Ohta T
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Clin Calcium
JT  - Clinical calcium
JID - 9433326
SB  - IM
MH  - Aged
MH  - Cost-Benefit Analysis
MH  - Humans
MH  - Japan
MH  - Middle Aged
MH  - Osteoporosis/*drug therapy/*economics
RF  - 20
EDAT- 2004/12/04 09:00
MHDA- 2005/03/18 09:00
CRDT- 2004/12/04 09:00
PHST- 2004/12/04 09:00 [pubmed]
PHST- 2005/03/18 09:00 [medline]
PHST- 2004/12/04 09:00 [entrez]
AID - 041116971703 [pii]
PST - ppublish
SO  - Clin Calcium. 2004 Nov;14(11):39-45.